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The 10q26 locus in the second intron of FGFR2 is the locus most strongly associated with estrogen-receptor-positive breast cancer
in genome-wide association studies. We conducted fine-scale mapping in case-control studies genotyped with a custom chip
(iCOGS), comprising 41 studies (n ¼ 89,050) of European ancestry, 9 Asian ancestry studies (n ¼ 13,983), and 2 African ancestry
studies (n ¼ 2,028) from the Breast Cancer Association Consortium. We identified three statistically independent risk signals within
the locus. Within risk signals 1 and 3, genetic analysis identified five and two variants, respectively, highly correlated with the most
strongly associated SNPs. By using a combination of genetic fine mapping, data on DNase hypersensitivity, and electrophoretic
mobility shift assays to study protein-DNA binding, we identified rs35054928, rs2981578, and rs45631563 as putative functional
SNPs. Chromatin immunoprecipitation showed that FOXA1 preferentially bound to the risk-associated allele (C) of rs2981578
and was able to recruit ERa to this site in an allele-specific manner, whereas E2F1 preferentially bound the risk variant of
rs35054928. The risk alleles were preferentially found in open chromatin and bound by Ser5 phosphorylated RNA polymerase
II, suggesting that the risk alleles are associated with changes in transcription. Chromatin conformation capture demonstrated
that the risk region was able to interact with the promoter of FGFR2, the likely target gene of this risk region. A role for
FOXA1 in mediating breast cancer susceptibility at this locus is consistent with the finding that the FGFR2 risk locus primarily pre-
disposes to estrogen-receptor-positive disease.Introduction
Multiple genome-wide association studies (GWASs) have
identified common variants on 10q26 associated with
estrogen-receptor-positive (ERþ) breast cancer. These
SNPs are the most strongly associated common variants
identified for breast cancer1–8 and map to the second
intron of FGFR2 (MIM 176943). Previous fine-scale map-
ping of this locus, together with analysis of evolutionary
conservation and accessible chromatin, pointed to SNP
rs2981578 being the most likely candidate causative
variant.8,9 Biochemical analysis of protein-DNA interac-
tions at the risk locus also suggested rs2981578 as a func-
tional variant, with the cancer-risk allele preferentially
binding OCT1/RUNX2 in vitro.10 siRNA experiments
indicated that changes in RUNX2 can affect FGFR2
expression levels.11 However, in vivo chromatin immuno-
precipitation (ChIP) assays found low levels of enrich-
ment for OCT1/RUNX2 at this site,10 suggesting that
the mechanism by which risk is conferred at this locus
has not yet been resolved. Experiments aimed at identi-
fying the target gene(s) of this risk locus have implicated
FGFR2, but the effects of the potential risk SNPs are still
debated.10,12,13
Here we present the results of comprehensive fine-scale
mapping of the FGFR2 locus by using dense SNP geno-
typing in 52 case-control studies from populations of Eu-
ropean, Asian, and African American ancestry within the
Breast Cancer Association Consortium (BCAC). Further-
more, we examine allele-specific binding by FOXA1,
ERa, E2F1, and RNA polymerase II to the candidate
causal risk SNPs and propose a mechanism by which
these SNPs may function to increase the risk of ERþ
disease.Germany; 106Frauenklinik der Stadtklinik Baden-Baden, 76532 Baden-Baden,
University, u. Polabska 4, 70-115 Szczecin, Poland; 108Postgraduate School o
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Genetic Mapping
Genotyping was conducted with a custom Illumina iSelect array
(iCOGS) (for details see Michailidou et al.6). For this project,
we identified SNPs across a 500 kb interval (positions
123,210,010–123,710,010 [NCBI build 37 assembly]) from the
1000 Genomes Project. This interval encompassed all known
SNPs correlated (r2 > 0.1) with the candidate causal variant,
rs2981578. At the time of the chip design (March 2010), the 1000
Genomes Project had cataloged 3,431 variants with a minor allele
frequency (MAF)> 2% in Europeans. From this catalog, we selected
all SNPs correlated with rs2981578 (r2 > 0.1) plus a set of SNPs
tagging all remaining variants (at r2 > 0.9). In total, 490 SNPs were
designed for the iCOGS chip, of which 438 were successfully geno-
typed and passedquality control (seeMichailidou et al.6 for details).
After quality-control exclusions, genotypes were available for
89,050 individuals of European ancestry from 41 studies, 13,983
individuals from 9 Asian studies, and 2,048 individuals from 2 Af-
rican ancestry studies.6 All studies were approved by the relevant
local ethics review committee and subjects gave informed consent.Statistical Analysis
The genotype data were first used to estimate genotypes for other
common variants across the region in the study subjects by impu-
tation, with IMPUTE v.2.2 and the March 2012 release of the 1000
Genomes Project as reference panel. Genotypes at 2,291 SNPs
could be imputed with imputation r2 > 0.3. Per-allele ORs for
each SNP were estimated by logistic regression, including study
and principal components (seven in Europeans, two in Asians,
and two in African Americans) as covariates, to allow for
potential population stratification as previously described.6
To determine the minimal number of SNPs independently
associated with breast cancer for each ethnicity, forward stepwise
logistic regression analysis was applied (with the R function step)
to all SNPs with a MAF > 0.02 for which evidence of associationGermany; 107Department of Genetics and Pathology, Pomeranian Medical
f Molecular Medicine, Warsaw Medical University, ul. _Zwirki i Wigury 61,
and; 110International Agency for Research on Cancer, 69372 Lyon Cedex
Athens 15310, Greece; 112Department of Internal Medicine, James Compre-
113Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan;
aiwan; 115Taiwan Biobank and Cancer Center and Department of Surgery,
wan; 116Division of Breast Cancer Research, Institute of Cancer Research,
y of Human Genetics. All rights reserved.
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(p value < 1 3 104) was observed in the single-SNP analysis. The
p value for each SNP, after adjustment for all other SNPs, was deter-
mined by a Wald test. Haplotype-specific ORs and confidence
limits were estimated with the haplo.stats package in R, with
adjustment for study and principal components.
Cell Lines
Breast cancer cell lines MDA-MB-134, ZR-75-1, T47D, and MCF-7
were grown in RPMI medium with 10% FCS and antibiotics under
standard conditions. These cell lines were from the CRUK Cam-
bridge Institute’s tissue culture collection. The normal breast
epithelial cell line BRE80 (provided as a gift from Roger Reddel,
CMRI, Sydney) was grown in DMEM/F12 medium with 5% horse
serum (HS), 10 mg/ml insulin, 0.5 mg/ml hydrocortisone, 20 ng/ml
epidermal growth factor, 100 ng/ml cholera toxin, and antibiotics.
Genotyping
Genomic DNA sequences from ZR-75-1, T47D, and MDA-MB-134
cells were amplified with primer pairs P1, P2, and P3. Resulting
fragments were isolated and directly sequenced by GATC-Biotech.
Additional cell lines were genotyped with fluorescent 50 exonu-
lease assay (TaqMan, predesigned assay) or by sequencing. Rele-
vant genotypes are listed in Table S2 available online.
Electrophoretic Mobility Shift Assays
Small-scale nuclear extracts and bandshifts were carried out as pre-
viously described10 and oligonucleotide sequences used in the as-
says are listed in Table S1. Competitor oligonucleotides were used
at 10-, 30- and 100-foldmolar excess as stated. Additional oligonu-
cleotides used as competitors in Figure S2 were as listed on the
Santa Cruz website.
Chromatin Immunoprecipitation
ChIP experiments were carried out as previously described.14 DNA
was quantitated with Quant-IT and equal amounts of precipitate
and input used in RT-PCR reaction with SYBR green master mix
on a 7900HT RT-PCR System (Applied Biosystems). Primers are
given in Table S1. Allele-specific PCR was carried out with TaqMan
Genotyping Assays (predesigned assays, ABI). Polyclonal anti-
bodies against FOXA1 (ab5089 and ab23738, Abcam, UK at 1:1 ra-
tio), ERa (sc543x, Santa Cruz Biotech), and E2F1 (C-20) (sc-193-x,
Santa Cruz Biotech) were used in ChIP experiments. All values ob-
tained are normalized to input and enrichment is given relative to
the negative CCND1 control.15 To account for the slight variations
in the levels of FOXA1 and E2F1 protein (Figure S1) and efficiency
of the ChIP in the different cell lines, positive controls were
included in each ChIP experiment: the GREB1 (MIM 611736) pro-
moter (pGREB)16 for FOXA1, MFAP1 (MIM 600215) for E2F1, and
heme oxygenase (HMOX1 [MIM 141250]) for RNA polymerase II.
Antibodies for Ser5P RNA polymerase II (ab5131) were also ob-
tained from Abcam, UK. In these experiments primer pairs from
the genomic region of 8q24 (see Table S1) were used as negative
control. Each ChIP has yielded similar results in at least two inde-
pendent experiments. For the rs2981578 TaqMan assay, titrations
were carried out to show that Ct values were directly proportional
to input for each of the alleles. The error bars denote the standard
deviation in three technical replicates. The data are also presented
in the form of allelic discrimination (AD) plots. The AD plots are
obtained from a TaqMan assay in which two different fluoro-
phores are each linked to a probe detecting the two different
alleles. Amplification of each allele was followed with an AppliedThe American JouBiosystems Real Time PCR machine (7900HT) and the data
analyzed with the SDS software. The SDS software converts the
raw data to fluorescence intensity for each allele and then plots
the results as a scatter graph of allele X versus allele Y.
FAIRE
Formaldehyde-assisted isolation of DNA regulatory elements
(FAIRE) relies on crosslinking of nucleosomes to DNA, with1%
formaldehyde for 10 min, followed by the isolation of noncross-
linked DNA. The isolated DNA is enriched for regulatory elements
that are in an open chromatin conformation.17 FAIRE was carried
out in MDA-MB-134 cells grown in full medium. Sonicated
genomic T47D and ZR-75-1 DNA was included in the genotyping
assay to indicate the position of risk and nonrisk homozygotes in
the allelic discrimination plots.
Chromatin Conformation Capture
Chromatin conformation capture (3C) libraries were generated
with EcoRI as described previously.18 3C interactions were quanti-
tated by real-time PCR (qPCR) with primers designed within
EcoRI restriction fragments (Table S3). qPCR was performed on a
RotorGene 6000 with MyTaq HS DNA polymerase (Bioline) with
the addition of 5 mM of Syto9, annealing temperature of 66C,
and extension of 30 s. 3C analyses were performed in two inde-
pendent experiments with each experiment quantified in tripli-
cate. BAC clone RP11-62L18 covering the 10q26 region was used
to create an artificial library of ligation products in order to
normalize for PCR efficiency. Data were normalized to the signal
from the BAC clone library and, between cell lines, by reference
to a region at within GAPDH (MIM 138400). All qPCR products
were electrophoresed on 2% agarose gels, gel purified, and
sequenced to verify the 3C product.
siRNA Transfections
Cells were grown to 50% confluence in 6-well plates. Transfections
were carried out according to manufacturer’s instructions with
10 ml lipofectamine RNAiMAX (Invitrogen) in a total of 3 ml
OptiMEM medium (Invitrogen), with siRNAs at a final concentra-
tion of 50 nM. A custom siRNA against FOXA1 (50-GAGAGAA
AAAAUCAACAGC-30)16,19 and the On-TARGET plus nontargeting
pool (D001810) negative control were obtained from Thermo
Fisher Dharmacon. After 6–24 hr the transfection mix was re-
placed with normal growth medium and cells were harvested after
48 hr by scraping into cold PBS. After washing in PBS at 4C,
samples were split in two. For protein analysis, samples were
resuspended in RIPA buffer plus protease inhibitors (Roche) and
frozen on dry ice and depletion of the relevant protein was
confirmed by immunoblot. For RNA isolation, samples were resus-
pended in 13 RLTand the Allprep kit (QIAGEN) was used to purify
nucleic acids.
Gene Expression Analysis
Gene expression in siRNA-transfected samples was analyzed by
RT-PCR for FOXA1 (MIM 602294) and normalized against the
housekeeping gene DGUOK (MIM 601465) with SYBR green
PCR Mastermix. Oligonucleotides were designed with Primer 3
(v.0.4.0) and sequences are given in Table S1. FGFR2 mRNA
levels were measured by TaqMan assay (FGFR2 Taqman assay
Hs00240796m1) and normalized against GAPDH (Taqman prede-
veloped assay 4333764T) from Applied Biosystems. Expression of
FOXA1 and FGFR2 after transfection of siRNA is given relative tornal of Human Genetics 93, 1046–1060, December 5, 2013 1049
the control transfected cells. All transfections were carried out in
triplicate.
Gene Expression Correlations and Statistical Analysis
Evidence for association between gene expression levels and SNP
genotypes was evaluated with ANOVA. Gene expression data
was obtained from the METABRIC sample collection.20 Genotypes
for rs2981578 and rs35054928 were determined with the probes
A-8465362 and A-8444843 on the Illumina SNP 6 array.Results
Fine-Scale Genetic Mapping
In total, 438 genotyped and 2,291 well-imputed SNPs were
considered, of which 392 SNPs were associated with breast-
cancer risk in at least one ethnic group at p < 104
(Table S4 and Figure 1). All associations were confined to
ERþ disease, with no evidence of association with ER-nega-
tive (ER) breast cancer (Table S5). Gene annotations and
chromatin modifications across the genotyped region are
shown in Figure 1D.
Results from the European Ancestry Studies
A total of 375 SNPs were associated with breast-cancer risk
in European woman at p < 104 (Table S4). Stepwise logis-
tic regression identified three independent association sig-
nals. Within each signal we identified most likely causal
variants after excluding all variants having a likelihood
ratio < 1/100 relative to the best-associated SNP in each
signal (shown in Table 1 for overall breast cancer and Table
2 for ERþ disease).
Within signal 1 the strongest association was with the
insertion/deletion rs35054928 (MAF ¼ 0.44; OR per C
[insertion] allele ¼ 1.27; 95% CI 1.24–1.29, p value 6.8 3
10131, p value 0.06 after adjustment for SNPs in other sig-
nals for all tumors, 0.009 for ERþ tumors), but a further
four SNPs were potentially causal with a likelihood ratio
greater than 1/100. Signal 2 contains a single variant
rs45631563 (MAF ¼ 0.04; OR per A [minor] allele ¼ 0.80;
95% CI 0.76–0.85, p value 3.8 3 1015, adjusted p values:
3.09 3 1011 for all tumors, 1.26 3 1011 for ERþ tumors).
Signal 3 contained two correlated variants (r2 ¼ 0.99):
rs2981578 (MAF ¼ 0.50; OR per C allele ¼ 1.24; 95% CI
1.21–1.26; p value: 1.6 3 10106, conditional p value:
3.97 3 108 for all tumors, 1.98 3 106 for ERþ) and inser-
tion/deletion variant rs45631539.
Genotypes of potentially causal SNPs in signals 1 and
3 were correlated (e.g., r2 ¼ 0.79 for rs35054928 and
rs2981578) but the remaining signal 2 SNP was not corre-
lated with the others (see Table S6).
Results from the Asian Ancestry Studies
A total of 30 SNPs displayed association with breast-cancer
risk in Asian woman at p < 104 (Table S7). The top SNP in
Asians was rs2912781, which is highly correlated with
rs2981578 (r2¼ 0.97 in Asians and r2¼ 0.98 in Europeans),
the top SNP in signal 3 in Europeans. Based on stepwise1050 The American Journal of Human Genetics 93, 1046–1060, Decelogistic regression analysis (Tables 1 and 2), only
rs2981578 was independently associated with risk (condi-
tional p value: 0.0001 in Asians). Although SNP rs2912781
was also strongly associated with breast cancer in Euro-
peans, it was excluded as a likely causative variant because
it had a likelihood ratio< 1/500 relative to SNP rs2981578,
the top signal 3 SNP in Europeans (r2 ¼ 0.97 in Asians and
r2 ¼ 0.98 in Europeans).
Results from the African Ancestry Studies
One SNP displayed association with breast cancer in Afri-
can woman at p < 104 (Table S4). This SNP, rs74992784
(MAF ¼ 0.02; OR ERþ per minor allele ¼ 2.05; 95% CI
1.41–2.98; p value 0.0001), maps approximately 200 kb
upstream of FGFR2, in an intron of ATE1 (MIM 607103),
is not polymorphic in Europeans or Asians, and is not in
LD with any of the other risk SNPs. The second strongest
association was with SNP rs11200017 (MAF ¼ 0.05; OR
ERþ per minor allele ¼ 0.62; 95% CI 0.45–0.85; p value
0.003). In Europeans this SNP was associated with
increased risk (MAF ¼ 0.2; OR ERþ per minor allele ¼
1.16; 95% CI 1.13–1.19; p value 4.9 3 1034). However,
it is weakly correlated with the top SNPs in signals 1 and
3 and not significant after adjustment for these SNPs.
Haplotype Analysis
Haplotype analysis was performed with one tag SNP from
each of the three independent risk signals detected in
Europeans for ERþ breast cancer (Table 2). In Europeans
we observed four haplotypes with frequencies >1%, each
associated with a different level of risk (Table 3). The high-
est risk was conferred by the haplotype (haplotype 3)
carrying the risk alleles for both rs35054928 (signal 1)
and rs2981578 (signal 3) (OR: 1.33; 95% CI 1.31–1.34,
compared to the baseline haplotype, carrying the common
allele at all three SNPs). Although these two SNPs mark two
independent risk signals, they are physically very close
(only 120 bp apart). Haplotype 1, which carries the risk
allele at rs2981578 but not rs35054928, was associated
with an intermediate increased risk (OR 1.14; 95%
CI 1.1–1.18). Haplotype 2 carries the rare allele for
rs45631563 (signal 2) in addition to the risk allele at
rs2981578 and was associated with a reduced risk (OR
0.86: 95% CI 0.83–0.88) relative to the baseline haplotype.
rs45631563 lies approximately 5.6 kb from the other two
risk SNPs.
Haplotype 3 also conferred the highest risk in Asians
(OR 1.27: 95% CI 1.23–1.31). Haplotype 1 conferred an
increased risk, but the OR was higher than in Europeans
and was not significantly different from that conferred
by haplotype 3 (OR 1.24; 95% CI 1.17–1.31). Haplotype
2 was not associated with a different risk, relative to the
baseline haplotype, but it was relatively rare (frequency
1%) and the OR was consistent with that observed for
Europeans (OR 0.96; 95% CI 0.81–1.14).
Given the difference in the results obtained for Asians
and Europeans, we extended the haplotype analysis tomber 5, 2013
AB
C
D
Figure 1. Manhattan Plot of the FGFR2 Breast Cancer Risk Locus
(A–C) Genotyped and imputed SNPs are plotted based on their chromosomal position on the x axis and their overall p value (-log10
values) from (A) European BCAC studies, (B) Asian ancestry, and (C) African ancestry on the y axis.
(D) Chromatin configuration across the genotyped region from ENCODE. From top to bottom, lanes show RefSeq genes (FGFR2 and
ATE1), H3K4Me1 and H3K27Me1 histone modifications, DNase clusters, transcription factor ChIP, ChromHMM chromatin states in
GM12878, H1-hESC, K562, HepG2, HUVEC, HMEC, HSMM, NHEK, and NHLF cells, ER-a ChIA-PET, and RNA polymerase II ChIA-
PET in MCF-7 cells. The blue arrow highlights the position of the top SNP (rs35054928). ChromHMM color coding is as follows: bright
red, active promoter; light red, weak promoter; purple, inactive/poised promoter; orange, strong enhancer; yellow, weak enhancer; blue,
insulator; dark green, transcriptional transition; gray, repressed/heterochromatin.include the top SNP from signal 1 in the African American
analysis (Table S8). This revealed that the minor allele
of rs11200017 was protective in all three ethnicities.The American JouIt is more common in Asians than Europeans and is
always found in combination with the minor allele of
rs35054928. It might therefore partly explain whyrnal of Human Genetics 93, 1046–1060, December 5, 2013 1051
Table 1. Candidate Functional Variants within the Three Independent Association Signals in Europeans and Asians: Association Results for
Overall Breast Cancer
Signal
SNP
(Position) Alleles MAF
Europeans Asians
DHSb
(MCF7)
Known TF
Binding Siteb
OR
(95% CI)
p Trend
(adjusted)a
OR
(95% CI)
p Trend
(adjusted)a
1 rs35054928
(123340431)
-/C 0.44 1.27 (1.24–1.29) 6.8 3 10131
(0.06)
1.15 (1.10–1.21) 5.4 3 108
(0.771)
yes E2F1/FOXA1
rs34032268
(123341525)
C/A 0.42 1.27 (1.25–1.30) 3.5 3 10130 1.15 (1.09–1.21) 2.3 3 107 no no
rs2981579
(123337335)
G/A 0.43 1.27 (1.24–1.29) 5.7 3 10130 1.16 (1.1–1.22) 2.4 3 108 yes no
rs2912779
(123337182)
C/T 0.43 1.27 (1.24–1.29) 8.3 3 10130 1.16 (1.1–1.22) 1.7 3 108 yes no
rs2912780
(123337117)
T/C 0.42 1.27 (1.24–1.29) 1.7 3 10130 1.16 (1.1–1.22) 1.6 3 108 no no
2 rs45631563
(123349324)
T/A 0.035 0.80 (0.76–0.85) 3.8 3 1015
(3.1 3 1011)
1.02 (0.75–1.39) 0.89 (0.450) yes no
3 rs2981578
(123340311)
T/C 0.497 1.24 (1.21–1.26) 1.6 3 10106
(4.0 3 108)
1.19 (1.13–1.25) 2.9 3 1011
(0.0001)
yes E2F1/FOXA1
rs45631539
(123341009)
-/ins 0.499 1.24 (1.21–1.26) 4.5 3 10105 1.19 (1.13–1.25) 4.2 3 1011 no no
Abbreviations are as follows: MAF, minor allele frequency; DHS, DNase I hypersensitive site; TF, transcription factor; ins, insertion of TGGGAGGCCAAGG.
aAfter adjustment for the top SNPs in the other signals, in a logistic regression model including rs35054928, rs45631563, and rs2981578.
bTaken from the UCSC Genome Browser, hg19.rs35054928 is not independently associated with risk in
Asians, after adjustment for rs2981578.
Analysis of Protein-DNA Interactions
By using data from ENCODE, we examined DNase hyper-
sensitivity and known transcription factor binding at
each of the potential causative SNPs in risk signals 1, 2,
and 3 (Table 1) and selected for further analysis five SNPs
(rs35054928, rs2981579, rs2912779, rs2981578, and
rs45631563) that were found to be present in a DNase
hypersensitive site (DHS) in MCF-7 cells (UCSC Genome
Browser), because confirmed GWAS hits have been shown
to be enriched in open chromatin.21 Electrophoretic
mobility shift assays (EMSAs) were carried out for these var-
iants. For rs35054928 we detected binding by two protein
complexes. Competition experiments suggested that the
strong (lower) band is likely to be E2F1 (Figure 2A), which
has also been reported to bind at this site in vivo (UCSC
Genome Browser), whereas the weaker band could be
competed with SP1 oligonucleotides (Figure 2A). We
observed protein interaction at rs2981579, but no differ-
ence between alleles. Competition experiments indicated
that this oligonucleotide is bound by ERa in vitro (Figures
S2A and S1B), but ChIP-seq data suggest that this site is
not occupied by ERa in vivo (Figure S3).22 At rs2912779,
EMSA again showed no allele-specific differences in bind-
ing by an as yet unidentified protein (Figure S2A). For
rs2981578 in risk signal 3, we previously reported allele-
specific binding of OCT1/RUNX2 in an ER cell line. How-
ever, after further analysis in ERþ cell lines, we found that,
in addition to the OCT1/RUNX2 bands, there was strong
binding by FOXA1 in MCF-7 (Figure 3B) and also in1052 The American Journal of Human Genetics 93, 1046–1060, DeceT47D, ZR-75-1 (Figure S2C), and PMC42 nuclear ex-
tracts.10 At rs45631563 (signal 2), we detected binding by
a nuclear protein with a stronger affinity for the A allele
(Figure 2C), but extensive competition analysis did not
reveal the identity of this protein (Figures S2D and S2E).
Protein binding to rs11200017, the potential risk SNP in
African Americans, was assessed bioinformatically. These
analyses suggested that the G allele of this SNP preferen-
tially forms GATA and ETSmotifs, whereas the A allele gen-
erates a sequence homologous to winged-helix recognition
motifs.
To examine transcription factor binding in vivo by ChIP,
we genotyped ERþ cell lines for the risk SNPs rs35054928
and rs2981578. The SNPs are correlated (r2 ¼ 0.79 in Euro-
peans) and all cell lines examined were concordant for the
risk alleles at these SNPs (see Table S3 for full genotypes).
The following lines were chosen for further analysis: ZR-
75-1 (rs2981578 C/C) (risk homozygote), MDA-MB-134
(C/T) (heterozygote), and T47D (T/T) (nonrisk homozy-
gote). In all further allele-specific ChIP experiments, the
TaqMan probe for rs2981578 was utilized as read-out for
both SNPs, because the two SNPs are in closer proximity
(120 bp) than the resolution limit of the ChIP assay (about
400 bp).
In FOXA1-ChIP assays, the C allele of rs2981578 present
in ZR-75-1 (C/C) and MDA-MB-134 (C/T) was strongly
enriched compared to a negative control from the
CCND1 locus (Figure 3A). Binding at this site was found
to be even stronger than that observed for the positive
control pGREB. However, the T allele of this site was only
marginally enriched and ChIP in the heterozygous cell
line MDA-MB-134 showed 8.5-fold greater enrichmentmber 5, 2013
Table 2. Candidate Functional Variants within the Three Independent Association Signals in Europeans and Asians: Association Results for
ERþ Breast Cancer
Signal SNP (Position)
Europeans ERþ Asians ERþ
OR (95% CI) p Trend (adjusted)a OR (95% CI) p Trend (adjusted)a
1 rs35054928 (123340431) 1.33 (1.30–1.36) 1.2 3 10134 (0.009) 1.23 (1.16–1.31) 7.7 3 1011 (0.81)
rs34032268 (123341525) 1.33 (1.30–1.36) 3.1 3 10132 1.23 (1.15–1.31) 1.9 3 1010
rs2981579 (123337335) 1.33 (1.30–1.36) 6.6 3 10133 1.23 (1.16–1.31) 5.8 3 1011
rs2912779 (123337182) 1.33 (1.30–1.36) 7.3 3 10133 1.23 (1.15–1.31) 4.1 3 1011
rs2912780 (123337117) 1.33 (1.30–1.36) 1.2 3 10132 1.23 (1.16–1.31) 4.2 3 1011
2 rs45631563 (123349324) 0.74 (0.69–0.79) 4.5 3 1019 (1.26 3 1011) 1.10 (0.73–1.66) 0.63 (0.22)
3 rs2981578 (123340311) 1.28 (1.25–1.31) 3.3 3 10104 (1.98 3 106) 1.26 (1.19–1.34) 1.2 3 1013 (0.0001)
rs45631539 (123341009) 1.28 (1.25–1.31) 7.8 3 10103 1.26 (1.19–1.35) 1.8 3 1013
aAfter adjustment for the top SNPs in the other signals, in a logistic regression model including rs35054928, rs45631563, and rs2981578.for the C allele. Moreover, allelic discrimination plots
(Figure 3B) confirmed that FOXA1-precipitated DNA
from this cell line clustered with the homozygous (C/C)
ZR-75-1 samples, further demonstrating the strong allele-
specific binding of FOXA1 at this SNP. Inspection of the
position weight matrix for FOXA1 confirmed that
rs2981578 overlaps a region of homology to the consensus
binding site for this transcription factor (Figure 3F), espe-
cially in those base pairs contacting the major groove
(RTTTR). Of interest, the allelic discrimination displayed
by FOXA1 when binding to chromatin in vivo was not
detectable in EMSAs via naked DNA (Figure 2B). We also
examined allele-specific binding of RUNX2 in MDA-MB-
134 cells but obtained either no or low enrichment with
no evidence of allele-specific binding (data not shown).
ChIP-seq data in ZR-75-1 cells suggested the presence of
an ERa binding site adjacent to the FOXA1 binding site22
(Figure S3A). We hypothesized that the pioneer factor
FOXA1 might be responsible for recruiting ERa to this
site. We therefore carried out ER-ChIP in the same set of
cell lines and found that ERa binding recapitulates
FOXA1 binding. In both ZR-75-1 (C/C) and MDA-MB-
134 (C/T), there was clear enrichment for the C allele
(Figure 3C). However, total levels of binding were low, sug-
gesting that the strong peak seen in ChIP-seq (Figure S3A)
is generated by a distinct site (see below). The T allele
showed no enrichment (Figure 3C), whereas the positive
ChIP control (pGREB) displayed good enrichment in all
cell lines tested (Figure 3D). The allelic discrimination
plot (Figure 3E) again confirms the strong bias of binding
in favor of the risk allele.
In order to exclude any effect of additional SNPs that
might influence ER binding, we sequenced the region over-
lapping the FOXA1 and ERa ChIP-seq peaks. When
comparing ZR-75-1, MDA-MB-134, and T47D, we found
two additional SNPs that were polymorphic in these cell
lines: rs111729099 (deletion of C) and rs11599804 (G/A).
By using an EMSA with the ER consensus binding site,
we examined whether sequences overlapping these SNPsThe American Joucould compete for ER binding in an allele-specific manner.
Figure S3B shows that sequences overlapping rs111729099
did not compete for binding. In contrast, an oligonucleo-
tide overlapping rs11599804 was able to compete for ERa
binding, but both alleles behaved identically. We therefore
conclude that the difference in ERa binding we observe at
rs2981578 is probably due to differential binding of
FOXA1 to this SNP, which is able to recruit ERa.
We next examined E2F1 binding at rs35054928 in the
same cell lines. ChIP experiments with a nonallelic probe
showed that there is a 2.4-fold enrichment of E2F1 bind-
ing at the risk allele (ZR-75-1), whereas little enrichment
was seen at the nonrisk allele (T47D) (Figure 4A). In the
heterozygous cell line MDA-MB-134, enrichment was
low but nevertheless there was preferential binding of
the risk allele in this cell line as shown in the allelic
discrimination plot (Figures 4A and 4B). Figure 4C indi-
cates weak homology of the sequence surrounding
rs35054928 to the E2F1 consensus binding site. ChIP
was also carried out with SP1 antibodies but no enrich-
ment or allele-specific binding was detectable at this site
(data not shown).
Having detected allele-specific binding by FOXA1 and
E2F1, we examined the transcriptional activity of the locus
by assaying binding of RNA polymerase II at the risk SNPs
via ChIP. We used antibodies against the serine-5-phos-
phorylated (Ser5P) form of this enzyme, which catalyzes
transcriptional initiation and elongation and has been
shown to be a good read-out for transcriptional activ-
ity.23 Figure 5 shows that Ser5P-Pol II can be precipitated
at the rs2981578 site. In the heterozygous cell line MDA-
MB-134, there was a 3.8-fold greater enrichment of the C
over the T allele (Figure 5A), which is visualized in the
allelic discrimination plot (Figure 5B). This finding sug-
gests that the risk allele (C) increases transcription. The
increased binding of FOXA1 and RNA polymerase II is
also reflected in increased chromatin accessibility of the
risk allele, as shown by allele-specific sequence retrieval
in a FAIRE assay (Figure 5C).rnal of Human Genetics 93, 1046–1060, December 5, 2013 1053
Table 3. FGFR2 Risk Haplotype Analysis in Europeans and Asians
rs35054928a rs2981578b rs45631563c Frequency OR p1 df 95% CIs
Haplotypes in Europeans ERþ
1 (2.4) 1 2 1 0.025 1.14 3.6 3 1004 1.10–1.18
2 (2.6) 1 2 2 0.035 0.86 3.3 3 1006 0.83–0.88
3 (2.9) 2 2 1 0.428 1.33 1.7 3 10125 1.31–1.34
Rare * * * 0.004
Baseline 1 1 1 0.509
Haplotypes in Asians ERþ
1 (2.4) 1 2 1 0.090 1.24 1.1 3 1004 1.17–1.31
2 (2.6) 1 2 2 0.010 0.96 8.2 3 1001 0.81–1.14
3 (2.10) 2 2 1 0.453 1.27 4.1 3 1013 1.23–1.31
Rare * * * 0.000
Baseline 1 1 1 0.446
In the first column, 1 indicates major genotype in Europeans and 2 indicates minor genotype in Europeans.
a1 indicates - allele, 2 indicates C allele.
b1 indicates T allele, 2 indicates C allele.
c1 indicates A allele, 2 indicates T allele.siFOXA1 Can Reduce FGFR2 Expression
Previous studies have implicated FGFR2 as a target of the
10q26 risk locus. To confirm a role of FOXA1 in FGFR2
expression, we transfected T47D and ZR-75-1 cells with
siRNA against FOXA1 and examined FOXA1 and FGFR2
expression 48 hr after transfection. Figure 6 shows that
FGFR2 expression was repressed to 34% of its pretransfec-
tion level in T47D (Figure 6A) cells and to 12% in ZR-
75-1 cells (Figure 6B). These results are consistent with
FOXA1 having a more pronounced effect in cells carrying
the risk genotype. However, FGFR2 contains multiple addi-
tional FOXA1 binding sites that may contribute to the
observed results. Transfection of siE2F1 had little effect
on FGFR2 expression (data not shown), but it also caused
a small upregulation of FOXA1, making these data hard
to interpret.
Genotype-Expression Correlations
To examine the potential target gene(s) underlying the
SNP associations, we used microarray data from 1,920
breast tumors (METABRIC20) to assess associations be-
tween the expression of genes within a 1Mb interval of
the risk SNPs (including FGFR2, ATE1 [MIM 607103],
NSMCE4A [MIM 612987], and TACC2 [MIM 605302])
and the presence of the risk genotypes at rs2981578
and rs35054928 by using the probes A-8465362 and
A-8444843, respectively, of the Illumina SNP6 array (corre-
lated to the two risk SNPs with r2 ¼ 0.935 in each case). No
significant associations with expression were observed.
Expression levels of FGFR2 and NSMCE4A by genotype in
both normal and tumor samples are shown in Figure S4.
However, RNA Pol II ChIA-PET experiments in MCF-7 cells
(Figure 1D) indicate that the putative regulatory region
encompassing the top SNPs interacts with the FGFR2 pro-1054 The American Journal of Human Genetics 93, 1046–1060, Decemoter, whereas no interactions with neighboring genes
were detected, suggesting that FGFR2 is the likely target.
To examine whether the risk SNPs might function in a
restricted cell population, we then examined the distribu-
tion of FOXA1 protein in normal mammary epithelial tis-
sue. Consistent with previous studies,24 Figure S5 shows
that in the human mammary gland, FOXA1 is found in
the nucleus of a subset of luminal epithelial cells only.
Given this restricted tissue distribution, in the future it
may be possible to carry out more powerful genotype-
expression association analyses by using microdissected
epithelial tissue.The Risk Region Interacts with the FGFR2 Promoter
To provide further evidence for FGFR2 being the target
gene, we examined the physical interaction between the
risk SNPs and the FGFR2 promoter via a 3C assay. Figure 7
shows that the putative regulatory element encompassing
the putative functional SNPs is able to interact with the
promoter sequences of FGFR2 in both ERþ (MCF-7 and
T47D) and ER (BRE-80) cell lines, strongly supporting
our conclusion that FGFR2 is the likely target gene of the
risk locus.Discussion
GWASs have now identified more than 70 breast-cancer
risk loci.6 However, our understanding of the mechanisms
by which these loci confer risk is still limited, and for the
large majority of GWAS hits neither the regulated target
genes nor the causative SNPs are known. At the 10q26
risk locus, the risk region maps to the second intron of
FGFR2, suggesting that FGFR2 itself is the likely targetmber 5, 2013
B A C Figure 2. Electrophoretic Mobility Shift
Assays for Candidate Causitive Variants
(A) rs35054928, (B) rs2981578, and (C)
rs45631563 were assayed with MCF-7
nuclear extracts. Labels above each lane
indicate inclusion of competitor oligonu-
cleotides at 10- and 30-fold molar excess
(A and B) and also at 100-fold molar excess
(C). For each SNP, the common allele is
shown on the left, the minor allele on
the right.gene, a hypothesis supported by previous studies reporting
association between presence of the risk allele and FGFR2
expression.10,12 However, functional and biochemical
studies of the likely causative SNPs have not fully ex-
plained the behavior of this risk locus.
Here we present extensive genetic fine mapping of this
locus with >2,200 imputed and genotyped SNPs in a
very large sample of breast-cancer cases and controls
from the BCAC. We have identified three independent
risk signals within this region, indicating that at least three
variants are likely to be causally implicated. We find evi-
dence of allele-specific transcription factor binding for
the most strongly associated SNP in each of the three risk
signals. Specifically, we detect in vivo allele-specific bind-
ing of E2F1 at rs35054928 and of FOXA1 and ERa at
rs2981578 in a cell line heterozygous for these SNPs. TF
binding is also reflected in allele-specific chromatin acces-
sibility and recruitment of RNA polymerase II to this sites,
which maps to a putative enhancer region. These results
suggest that these two SNPs are most likely to be causally
related to breast-cancer risk. At rs45631563, allele-specific
binding by a nuclear protein was detected in vitro. We do
not exclude the possibility that additional risk SNPs within
each signal may also contribute to function.
We found some differences in the pattern of association
between European and Asian women. Although clear evi-
dence of independent associations was observed in Euro-
peans for both rs35054928 and rs2981578, the analysis
in Asians found no evidence for rs35054928, after adjust-
ment for rs2981578. Haplotype analyses suggest that this
difference might be due to the confounding effect of the
third risk SNP (signal 2, rs45631563), for which the rare
allele is protective in Europeans with a similar trend in
Asians, where it is much rarer. The differences between
Europeans and Asians might also reflect other modifying
variants in the region, or other factors such as genetic back-
ground or differences in the distribution of tumor sub-
types. We found no clear evidence of association for these
SNPs in African Americans; however, the sample size was
much smaller and therefore there was less statistical power
in the fine-mapping analyses, particularly because a higher
proportion of breast cancer cases in African American
women are ER.The American JouThe pattern we report here, in which multiple indepen-
dent variants in a region contribute to disease risk, has also
been observed in fine-mapping studies of the CCND118
and TERT25 breast-cancer susceptibility regions, suggesting
that this may be a common feature. Because, as here,
neighboring SNPs are often correlated, it is difficult to
disentangle their independent effects, even in very large
epidemiological studies and in the presence of highly sta-
tistically significant associations. The haplotype carrying
the risk variants rs2981578 and rs35054928 confers an
estimated relative risk of 1.33 (relative to the baseline
haplotype), which puts it among the highest for a cancer
susceptibility locus identified through GWASs. This ex-
plains why the FGFR2 locus is the most readily identified
risk locus in breast-cancer GWASs. One might speculate
that, conversely, strong GWAS hits may tend to be the
result of multiple causal variants.
Recent genome-wide analysis suggests that FOXA1 bind-
ing sites are enriched among breast-cancer susceptibility
SNPs.26,27 Our observation of allele-specific binding
by FOXA1 to rs2981578 fits well with this result, but
we demonstrate that additional factors contribute to
cancer susceptibility. FOXA1 is known to act as a pioneer
factor, able to open closed chromatin, thereby allowing
the recruitment of additional factors, especially ERa.28
Our observation of allele-specific binding by ERa at
rs2981578 is fully consistent with such a model. It is
tempting to speculate that FOXA1 may provide a similar
function for the closely linked SNP rs35054928, for which
we have shown allele-specific binding by E2F1. The fact
that the FOXA1 binding allele is also present on a protec-
tive haplotype could also be explained in terms of its func-
tion as a pioneer factor. Once it has opened the chromatin,
either activation or repressing factors might be recruited
to its vicinity, as observed in gene expression studies after
siFOXA1 transfection.16
FOXA1 and ERa are part of a network of transcrip-
tional master regulators conferring estrogen responsive-
ness.16,24,29 Our findings that these two transcription
factors are involved in allele-specific regulation of FGFR2
are therefore fully consistent with our genetic association
analyses that show a much stronger effect of this risk locus
for ERþ disease, with little or no association for ER disease.rnal of Human Genetics 93, 1046–1060, December 5, 2013 1055
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Figure 3. ChIP Assay at the rs2981578
Site
(A–E) FOXA1 (A) and ERa (C and D) ChIP-
qPCR assays were carried out in the three
cell lines ZR-75-1, MDA-MB-134, and
T47D, each carrying a different genotype
for this SNP. A primer pair from the
CCND1 locus served as negative control,
and pGREB was used as positive control.
Error bars show standard deviation for
three technical replicates of a representa-
tive experiment. An allelic discrimination
plot of the same experiments is shown
for FOXA1 (B) and ERa (E) ChIPs. Abbrevi-
ation: NTC, nontemplate control.
(F) Position weight matrix, PWM, of
FOXA1 from JASPAR, with homology to
the () strand of risk (G) and nonrisk
(A) alleles of rs2981578 shown in blue
underneath.E2F1 is a key transcription factor in the control of prolif-
eration, in differentiation, and in the control of apoptosis.
In breast-cancer samples its expression correlates well
with other proliferation markers, is indicative of poor
outcome,30 and is independent of ER status. E2F1 may
therefore in principle contribute to risk for developing
both ERþ and ER disease, but our association data sug-
gest that the effect of rs35054928 on ER disease risk
is small. In addition, we have previously shown that
RUNX2 displays allele-specific binding at rs2981578, at
least in vitro,10 and may also contribute to risk in certain
breast-cancer subtypes or at specific stages of develop-
ment. High levels of RUNX2 have been found in triple-
negative tumors,31 but the association analyses suggest
that the effect of rs2981578 on the development of ER
tumors is also small.
A number of studies have addressed questions regarding
the biological effect of the presence of the FGFR2 risk1056 The American Journal of Human Genetics 93, 1046–1060, December 5, 2013SNPs: do the risk SNPs affect tran-
scription and what are their likely
target gene(s)? Our previous work
has suggested that the risk allele of
rs2981578 is able to drive transcrip-
tion more strongly than the nonrisk
allele.10 This conclusion is supported
by the evidence here that RNA poly-
merase II is preferentially recruited to
the risk alleles, at least in breast-cancer
cell lines. Binding of RNA polymerase
II was reported to mirror transcrip-
tion levels,23 but it is interesting to
note that within close vicinity of
rs2981578, there are multiple binding
sites for transcription factors associ-
ated with transcriptional repression
(NANOG, SIN3A, YY1, and HDAC2)
rather than transcriptional activation.
Our findings therefore suggest thatthe risk SNPs can affect transcriptional regulation but do
not necessarily determine the direction of change.
We also examined the likely target gene of the 10q26 risk
locus. Because of a lack of expressed SNPs in FGFR2 in the
heterozygous cell line MDA-MB-134, it was not possible to
assay allele-specific transcription. In a surrogate analysis
we found that FGFR2 expression is decreased after siFOXA1
transfection. Furthermore, we have recently found that
FGFR2-regulated genes cluster near GWAS hits, further
supporting a role for FGFR2 in mediating risk.27 We
attempted to assess associations between the newly identi-
fied potential causative SNPs and gene expression in 2,000
breast tumor samples from the METABRIC study but
did not find evidence of association with expression of
FGFR2 or any of the neighboring genes, a result consistent
with other recent studies.32,33 However, our 3C studies
confirm that the risk region interacts with the FGFR2
promoter in both ERþ and ER cell lines. These findings,
AB
C
Figure 5. Allele-Specific Polymerase Binding and Chromatin
Accessibility
(A) ChIP assay at the rs2981578 site with Ser5P-RNA Pol II-specific
antibodies. Enrichment is given relative to a negative control (NC)
primer pair from 8q24. The heme oxygenase promoter (HO) was
used as positive control and error bars show the standard deviation
of three technical replicates of a representative experiment.
(B) Allelic discrimination plot for the same experiment. NTC: non-
template control.
(C) Allelic discrimination plot of DNA at rs2981578 isolated after
FAIRE in the cell line MDA-MB-134. Genotyping results for
T47D and ZR-75-1 cells are shown as controls.
A
B
C
Figure 4. ChIP Assay for E2F1 at the FGFR2 Risk SNPs in ZR-75-1,
MDA-MB-134, and T47D Cell Lines
(A) Fold enrichment in a ChIP-qPCR experiment is shown relative
to a negative control from the PFKM promoter (MIM 610681);
MFAP1, positive control. Error bars show the standard deviation
for three technical replicates of a representative experiment.
(B) Allelic discrimination plot via the rs2981578 TaqMan probe;
NTC: nontemplate control.
(C) PWM of E2F1 from JASPAR, with the risk (C) and nonrisk ()
alleles of rs35054928 shown underneath.together with the known critical role of FGFR2 in the
developing mammary gland,34 make FGFR2 the most
likely target gene for mediating risk. Although additional
targets cannot be excluded, our conclusion is also consis-
tent with the recent description of FGFR2 kinase activating
mutations in breast cancer.35 It is possible that the effect of
regulatory SNPs can be detected only when examining
expression at the correct developmental stage or after the
relevant cell signaling stimuli.
The cell type in which FGFR2 risk SNPs mediate their
function has been debated.10,12,13 Most expression correla-
tions have employed whole-tissue sections. Ex vivo studies
of skin fibroblasts have detected higher FGFR2 expressionThe American Joulevels in the presence of the tagging risk SNPs.12 However,
we note that in normal breast tissue, FGFR2 is primarily ex-
pressed in epithelial cells.13 Such an expression pattern
mimics that of FOXA1, whose expression is also restricted
to the breast epithelium. These observations are consistent
with FOXA1 contributing to the risk phenotype byrnal of Human Genetics 93, 1046–1060, December 5, 2013 1057
Figure 7. Chromatin Conformation Assays with the FGFR2
Promoter as Bait
Adiagramof the FGFR2 locus indicating EcoRI sites is shown above
the panels depicting normalized interaction frequencies in the cell
lines indicated. MCF-7 and T47D are ERþ breast cancer cell lines,
and BRE-80 is an ER- transformed breast epithelial cell line. Error
bars depict the standard deviation of three biological replicates
assayed in duplicate. P, promoter; gray bar shows the risk region.
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Figure 6. Effect of siRNA Downregulation of FOXA1 on FGFR2
Expression
FOXA1 and FGFR2 RNA levels in (A) T47D and (B) ZR-75-1 cells.
Error bars represent variation in three independent transfection
experiments.binding to rs2981578 inmammary epithelial cells, thereby
promoting an increase in FGFR2 expression. However, a
more careful analysis of FGFR2 and FOXA1 will be required
to determine colocalization of expression, especially dur-
ing early mammary development when the risk SNPs
might exert their function.
In conclusion, we have demonstrated that susceptibility
to breast cancer at FGFR2 is conferred by at least three in-
dependent signals, indicating the presence of at least three
functionally relevant variants. We provide evidence that
FOXA1 and E2F1 mediate risk, most likely exerting their
effect in mammary epithelial cells.Supplemental Data
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